EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> The FDA cleared Transgene to start a phase 1 trial of its personalized immunotherapy TG4050 in ovarian cancer patients. NEC is co-financing the cancer vaccine trial. Release

> UniQure posted updated data on its hemophilia B gene therapy. The data show the high Factor IX activity seen early in the study has been sustained up to six months. Statement

> A phase 2 trial of Modus Therapeutics’ sickle cell disease drug failed to show a meaningful benefit. The setback led Modus to weigh its options for further development of the asset. Release  

Sponsored by Biotech Primer

September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that Drives Decision Making and Investments

Become fluent in the core elements of revenue forecasting including epidemiology, competitive assessments, market share assignment and pricing. Let Biotech Primer's dynamic industry experts teach you how to assess the value of new therapies.

> TreeFrog Therapeutics raised €7 million ($7.8 million). The French startup aims to move one of its cell therapy research programs into humans in 2024. Statement 

> Pfizer nominated a preclinical development candidate under its collaboration with Sosei Heptares, triggering a $3 million milestone payment. The partners are yet to disclose the target of the small molecule. Release  

> Ixaltis completed phase 2 development of its urinary incontinence drug, litoxetine, setting the French biotech up to move into phase 3. Statement  

Suggested Articles

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.

The buzzy life sciences company Verily is looking to speed up COVID testing with a new lab based at its native South San Francisco.

Although Genfit canned its NASH program last month, it has been plugging away at a blood-based diagnostic for the liver disease.